|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Microbial transformation of epoxides显示文摘 | Jelto S Jan A M de B | 1998 | Enzyme and Microbial Technology1998，22，： | 1 |
| 2 | Specific determinants of intrinsic work motivation,emotional exhaustion and turnover intention:A muhi-sample longitudinal study显示文摘 | Inge Houkes Janssen P M Jan de Jonge & Bakker A B | 2003 | Journal of Occupational and Organizational Psychology2003，，4： | 1 |
| 3 | A direct PCR detection method for clostridium tyrobutyricum spores in up to 100 Milliliters of raw milk显示文摘 | LIEVE M F H JAN H G E De B GUIDO M A V J W | 1995 | Appl Environ Microbiol1995，12，61： | 1 |
| 4 | Specific determinants of intrinsic work motivation, emotional exhaustion and turnover intention: A multi-sample longitudinal study显示文摘 | Inge Houkes Janssen P M Jan de Jonge and Bakker A B | 2003 | Journal of Occupational and Organizational Psychology2003，76，4： | 1 |
| 5 | 应用抑酸剂、H2受体拮抗剂和质子泵抑制剂升序或降序治疗新发消化不良的效果与成本效益分析(DIAMOND研究):一项基于初级保健的随机对照试验显示文摘背景在消化不良的初级保健中,医生的大量工作负担和高额的医疗费用均与治疗密切相关。尽管有关共识和指南已经形成,但该病最经济的初始治疗策略仍未明确。本研究对初级卫生保健中新发消化不良的升序与降序治疗作一比较。方法在新西兰年龄≥18、因新发消化不良就诊于家庭医生的患者均可纳入这项双盲、随机对照试验。2003年10月-2006年1月,采用计算机生成的序列(区块数为6),随机分配664例患者接受抑酸剂、H,受体拮抗剂、质子泵抑制荆升序(n=341)或降序(n=323)阶梯治疗。每阶段持续4周,只有在4周内症状持续或复发时,才能进入下一阶段。主要结局为6个月时症状缓解的情况以及初始治疗的成本效益。采用意向性治疗(ITT)分析,ITT人群包括所有在6个月时获得主要结局数据的患者。本试验已在ClinicalTrials.gov注册.注册号为NCT00247715。结果升序组332例、降序组313例达到观察终点,并获得了充分的评估数据;退出试验的主要原因是失访。治疗6个月后,升序组238例(72%)和降序组219例(70%)治疗获得成功(OR0.92,95%C10.7~1-3)。升序组的平均医疗费用低于降序组(E228 vs ∈245;P=0.0008),这主要是由于药物费用不同所致。升序组94例(28%)、降序组93例(29%)报告≥1次药物相关不良事件,但均不严重,包括消化不良症状、腹泻、便秘、口干/口苦等。结论在新发消化不良的初级保健中,尽管升序治疗与降序治疗的成功率相似,但在6个月时升序治疗策略显得更为经济划算。 | Corine J van Marrewijk Suhreta Mujakovic Gerdine A J Fransen Mattijs E Numans Niek J de Wit Jean W M Muris martijn G H van Oijen Jan B M J Jansen Diederik E Grobbee J Andre Knottnenus RobertJ F Laheij | 2009 | 世界临床医学2009，，7： | 0 |
| 6 | Management of extracranial carotid artery stenosis during endovascular treatment for acute ischaemic stroke:results from the MR CLEAN Registry显示文摘Background The optimal management of ipsilateral extracranial internal carotid artery(ICA)stenosis during endovascular treatment(EVT)is unclear.We compared the outcomes of two different strategies:EVT with vs without carotid artery stenting(CAS).Methods In this observational study,we included patients who had an acute ischaemic stroke undergoing EVT and a concomitant ipsilateral extracranial ICA stenosis of≥50%or occlusion of presumed atherosclerotic origin,from the Dutch Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands(MR CLEAN)Registry(2014-2017).The primary endpoint was a good functional outcome at 90 days,defined as a modified Rankin Scale score≤2.Secondary endpoints were successful intracranial reperfusion,new clot in a different vascular territory,symptomatic intracranial haemorrhage,recurrent ischaemic stroke and any serious adverse event.Results Of the 433 included patients,169(39%)underwent EVT with CAS.In 123/168(73%)patients,CAS was performed before intracranial thrombectomy.In 42/224(19%)patients who underwent EVT without CAS,a deferred carotid endarterectomy or CAS was performed.EVT with and without CAS were associated with similar proportions of good functional outcome(47%vs 42%,respectively;adjusted OR(aOR),0.90;95%CI,0.50 to 1.62).There were no major differences between the groups in any of the secondary endpoints,except for the increased odds of a new clot in a different vascular territory in the EVT with CAS group(aOR,2.96;95%CI,1.07 to 8.21).Conclusions Functional outcomes were comparable after EVT with and without CAS.CAS during EVT might be a feasible option to treat the extracranial ICA stenosis but randomised studies are warranted to prove non-inferiority or superiority. | Sabine L Collette Michael P Rodgers Marianne A A van Walderveen Kars C J Compagne Paul J Nederkoorn Jeannette Hofmeijer Jasper M Martens Gert J de Borst Gert Jan R Luijckx Charles B L M Majoie Aad van der Lugt Reinoud P H Bokkers Maarten Uyttenboogaart | 2023 | Stroke & Vascular Neurology2023，8，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员